文献速递呼吸道感染

类固醇治疗对肺炎旁胸腔积液结局的影响:STOPPE 先导随机临床试验

Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

STOPPE 为澳大利亚六中心先导、双盲、安慰剂对照随机试验,纳入社区获得性肺炎合并胸腔积液成人,按2:1随机接受静脉地塞米松4mg每日两次共48小时或安慰剂并随访30天。结果显示地塞米松在生命体征持续正常化时间、炎症标志物、胸腔引流比例、抗生素疗程及住院时长方面均无初步获益,且短暂高血糖更常见。

要点

  • 地塞米松未缩短生命体征持续正常化时间,中位41.0 vs 27.8小时,HR 0.729(95%CI 0.453-1.173),P=0.193。
  • 地塞米松组与安慰剂组胸腔引流比例分别为49.0%与42.9%(P=0.60),无显著差异。
  • 地塞米松组短暂高血糖发生率15.6%,高于安慰剂组的7.1%。

核心结论

  • 在肺炎旁胸腔积液成人中,全身性糖皮质激素未显示出初步获益。

研究设计与样本

  • 先导、多中心、双盲、安慰剂对照随机试验,涉及澳大利亚六个中心。
  • 社区获得性肺炎合并胸腔积液成人按2:1随机接受静脉地塞米松4mg每日两次共48小时或安慰剂,随访30天。
  • 共80例随机(1例治疗前退出),地塞米松组51例、安慰剂组28例接受治疗。

主要发现

  • 生命体征(体温、血氧饱和度、血压、心率、呼吸频率)持续(>12小时)正常化时间中位数:地塞米松组41.0小时(95%CI 32.3-54.5),安慰剂组27.8小时(95%CI 15.4-49.5),HR 0.729(95%CI 0.453-1.173),P=0.193。
  • C反应蛋白或白细胞计数无差异,但地塞米松组第3天白细胞计数更高。
  • 胸腔引流操作在地塞米松组49.0%、安慰剂组42.9%中实施(P=0.60)。
  • 胸部影像胸腔积液阴影随时间减少,组间无一致差异。
  • 平均抗生素疗程(22.4天[SD 15.4] vs 20.4天[SD 13.8])和中位住院时间(6.0天[IQR 5.0-10.0] vs 5.5天[IQR 5.0-8.0])两组相似。

临床怎么用

  • 对于社区获得性肺炎合并胸腔积液成人,不推荐常规使用全身性糖皮质激素以改善结局。
  • 使用地塞米松时需注意短暂高血糖风险。

局限性

  • 为先导试验,样本量小(80例随机),结果需更大规模试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Pleural effusion commonly complicates community-acquired pneumonia and is associated with intense pleural inflammation. Whether antiinflammatory treatment with corticosteroids improves outcomes is unknown. Objectives: To assess the effects of corticosteroids in an adult population with pneumonia-related pleural effusion. Methods: The STOPPE (Steroid Therapy and Outcome of Parapneumonic Pleural Effusions) trial was a pilot, multicenter, double-blinded, placebo-controlled, randomized trial involving six Australian centers. Patients with community-acquired pneumonia and pleural effusion were randomized (2:1) to intravenous dexamethasone (4 mg twice daily for 48 h) or placebo and followed for 30 days. Given the diverse effects of corticosteroids, a comprehensive range of clinical, serological, and imaging outcomes were assessed in this pilot trial (ACTRN12618000947202). Measurements and Main Results: Eighty patients were randomized (one withdrawn before treatment) and received dexamethasone (n = 51) or placebo (n = 28). This pilot trial found no preliminary evidence of benefits of dexamethasone in improving time to sustained (>12 h) normalization of vital signs (temperature, oxygen saturations, blood pressure, heart, and respiratory rates): median, 41.0 (95% confidence interval, 32.3-54.5) versus 27.8 (15.4-49.5) hours in the placebo arm (hazard ratio, 0.729 [95% confidence interval, 0.453-1.173]; P = 0.193). Similarly, no differences in C-reactive protein or leukocyte counts were observed, except for a higher leukocyte count in the dexamethasone group at Day 3. Pleural drainage procedures were performed in 49.0% of dexamethasone-treated and 42.9% of placebo-treated patients (P = 0.60). Radiographic pleural opacification decreased over time with no consistent intergroup differences. Mean duration of antibiotic therapy (22.4 [SD, 15.4] vs. 20.4 [SD, 13.8] d) and median hospitalization (6.0 [interquartile range, 5.0-10.0] vs. 5.5 [interquartile range, 5.0-8.0] d) were similar between the dexamethasone and placebo groups. Serious adverse events occurred in 25.5% of dexamethasone-treated and 21.4% of placebo-treated patients. Transient hyperglycemia more commonly affected the dexamethasone group (15.6% vs. 7.1%). Conclusions: Systemic corticosteroids showed no preliminary benefits in adults with parapneumonic effusions. Clinical trial registered with www.anzctr.org.au (ACTRN12618000947202).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Fitzgerald, Waterer, Budgeon, et al. Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial. Am J Respir Crit Care Med. 2022. PMID: 35081010. doi:10.1164/rccm.202107-1600OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。